Prophylaxis against Recurrence in Liver Transplantation Patients with Hepatitis B Virus: What is New?

Hepatitis B virus (HBV) causes an endemic infection that affects nearly 2 billion patients worldwide. It is one of the leading causes of liver cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation (LT). Recurrence of HBV infection after LT is due to specific HBV-host genome interactio...

Descripción completa

Detalles Bibliográficos
Autores principales: Harmancı, Özgür, Selçuk, Haldun, Haberal, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Ltd 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521236/
https://www.ncbi.nlm.nih.gov/pubmed/26356785
http://dx.doi.org/10.14218/JCTH.2014.00023
Descripción
Sumario:Hepatitis B virus (HBV) causes an endemic infection that affects nearly 2 billion patients worldwide. It is one of the leading causes of liver cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation (LT). Recurrence of HBV infection after LT is due to specific HBV-host genome interactions. Although hepatitis B immunoglobulin treatment constituted the backbone of HBV recurrence, use of the nucleoside and nucleotide analogs (especially the ones with a higher genetic barrier to resistance), either alone or in combination, offer us new and powerful options in overcoming this serious issue.

Ejemplares similares